Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.
Free White Paper
Week in Review: Cellular Biomedicine of China to Reverse Merger in US
publication date: Jan 5, 2013
author/source: Richard Daverman, PhD
Cellular Biomedicine Group (CBMG), a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group (OTCQB: EBIG) (see story). EastBridge is a
Sichuan Kelun Pharma (SHE: 002422) will spend $135 million to purchase a 12.3% stake in Lijun International Pharma (HK: 2005) (see story). Both companies are involved in the IV drug market in
ChinaBio® in the News
Hong Kong, China
June 15–17, 2016